Last reviewed · How we verify
DaxibotulinumtoxinA for injection
DaxibotulinumtoxinA is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.
DaxibotulinumtoxinA is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis. Used for Glabellar lines (frown lines) for aesthetic use, Cervical dystonia, Blepharospasm.
At a glance
| Generic name | DaxibotulinumtoxinA for injection |
|---|---|
| Sponsor | Revance Therapeutics, Inc. |
| Drug class | Botulinum toxin |
| Target | SNARE complex (acetylcholine release machinery) |
| Modality | Biologic |
| Therapeutic area | Aesthetics, Neurology |
| Phase | Phase 3 |
Mechanism of action
DaxibotulinumtoxinA works by cleaving SNARE proteins required for acetylcholine vesicle release, preventing neuromuscular transmission and inducing muscle relaxation. The drug is formulated with a proprietary peptide excipient (RTP004) designed to enhance potency and duration of action compared to other botulinum toxin formulations. This mechanism is utilized for aesthetic and therapeutic indications where temporary muscle paralysis is therapeutically beneficial.
Approved indications
- Glabellar lines (frown lines) for aesthetic use
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
Common side effects
- Headache
- Injection site reactions
- Muscle weakness
- Eyelid ptosis
- Facial asymmetry
Key clinical trials
- DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia (PHASE1, PHASE2)
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine (PHASE3)
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine (PHASE3)
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
- A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DaxibotulinumtoxinA for injection CI brief — competitive landscape report
- DaxibotulinumtoxinA for injection updates RSS · CI watch RSS
- Revance Therapeutics, Inc. portfolio CI